Cat. No.: HY-101213

OSW-1

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

OSW-1, isolated from Ornithogalum caudatum, is a specific antagonist of ooxysterol binding protein (OSBP) and OSBP-related protein 4 (ORP4) with GI₅₀s in the nanomolar range in human cancer lines.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 97.00%
CAS No.: 145075-81-6
Formule: C₄₇H₆₈O₁₅
Masse moléculaire:873.03

Stockage:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

OSW-1 Chemical Structure

CAS No.: 145075-81-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

OSBP/ORP4^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	27 nM Compound: OSW-1	Cytotoxicity against human A549 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human A549 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
BJ	IC₅₀	0.2 nM Compound: OSW-1	Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
CCRF-CEM	IC₅₀	0.3 nM Compound: OSW-1	Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
G-361	IC₅₀	1 μM Compound: OSW-1	Cytotoxicity against human G361 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human G361 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
HCT-116	IC₅₀	8400 nM Compound: OSW-1	Cytotoxicity against human HCT116 assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HCT116 assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
HeLa	IC₅₀	3.4 nM Compound: OSW-1	Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
HeLa	IC₅₀	2.6 nM Compound: 1, OSW-1	Cytotoxicity against human HeLa cells after 24 hrs by XTT assay Cytotoxicity against human HeLa cells after 24 hrs by XTT assay	[PMID: 24613377]
HL-60	IC₅₀	0.00025 μM Compound: 3	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11170674]
HL-60	IC₅₀	0.25 nM Compound: 3	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11170674]
HOS	IC₅₀	8200 nM Compound: OSW-1	Cytotoxicity against human HOS cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HOS cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
Ishikawa	IC₅₀	3 μM Compound: 5f (OSW-1)	Inhibition of the necrosis induced by compound in endometrial cancer ishikawa cell line after 24 hr Inhibition of the necrosis induced by compound in endometrial cancer ishikawa cell line after 24 hr	[PMID: 15149699]
MCF7	IC₅₀	7 μM Compound: 5f (OSW-1)	Inhibition of the necrosis induced by compound in breast cancer MCF-7 cell line Inhibition of the necrosis induced by compound in breast cancer MCF-7 cell line	[PMID: 15149699]
MCF7	IC₅₀	2.4 nM Compound: OSW-1	Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]
MDA-MB-231	IC₅₀	0.5 μM Compound: 5f (OSW-1)	Inhibition of the necrosis induced by compound in breast cancer MDAMB-231 cell line Inhibition of the necrosis induced by compound in breast cancer MDAMB-231 cell line	[PMID: 15149699]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	0.78 nM Compound: OSW-1	Growth inhibition of human NCI60 cells Growth inhibition of human NCI60 cells	[PMID: 31126855]
T98	IC₅₀	70 nM Compound: OSW-1	Cytotoxicity against human T98 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human T98 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 21438635]

In Vitro

OSW-1 has a strong inhibitory effect on colon carcinoma cells with low cytotoxicity on normal cells. The anti-proliferative effects of OSW-1 on SW480 and LoVo colon carcinoma cells are characterized by measuring cell viability using the CCK8 assay, and compared the results with other clinical anticancer agents. SW480 and LoVo cell lines are derived from a Dukes' stage B colon carcinoma and a colon carcinoma metastatic nodule, which represent non-metastatic and metastatic carcinomas, respectively. OSW-1 exhibits not only extremely strong anticancer activity in SW480 and LoVo cell lines with an IC₅₀ of nanomolar concentration, but is also more potent than other anticancer agents by 10-100 times, with a lower cytotoxic effect on normal epithelial cells. These results indicate that OSW-1 has a powerful anticancer effect, but lower cytotoxic effect on normal cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To ascertain whether or not OSW-1 is as effective in vivo, a nude mouse model inoculated by LoVo cells is adopted, in which OSW-1 treatment is performed when tumors became palpable. The results show that the size of tumors in treated mice is smaller on average than control mice. The significant difference is observed from the 15-17 th day following treatment, and this difference is gradually increased until the animals are sacrificed. Compared with the control group, the tumor weight of the OSW-1-treated group significantly decreases (P<0.05). Additionally, no apparent side effects are observed in OSW-1-treated mice. These results demonstrate that OSW-1 has powerful effects on suppressing colon tumor growth without significant side effects in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 145075-81-6
Appearance Solid
Masse moléculaire 873.03
Formule C₄₇H₆₈O₁₅
Color White to off-white
SMILES

C[C@@]1([C@@]2(O)[C@H](C)C(CCC(C)C)=O)[C@](C[C@@H]2O[C@@](OC[C@H](O)[C@@H]3O[C@@](OC[C@@H](O)[C@@H]4O)([H])[C@@H]4OC(C5=CC=C(OC)C=C5)=O)([H])[C@@H]3OC(C)=O)([H])[C@@](CC=C6[C@@]7(CC[C@H](O)C6)C)([H])[C@]7([H])CC1
Structure Classification
- Steroids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (5)

All IFFlow CytometryWBRT-PCR

Sort by:

Journal Impact Factor

Nat Cell Biol

The bridge-like lipid transport protein VPS13C/PARK23 mediates ER-lysosome contacts following lysosome damage. [Abstract]

2025 Apr 10. PMID: 40211074
Mol Neurobiol

OSBP Participates in Neural Damage Repair by Regulating Lysosome Transport Under Oxidative Stress. [Abstract]

2025 Jun;62(6):7557-7575. PMID: 39915357
Oncol Lett

OSW-1 inhibits tumor cell proliferation and migration via uncoupling protein 2 in hepatocellular carcinoma. [Abstract]

2025 May 22;30(1):361. PMID: 40469918

OSW-1 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2025 May 22;30(1):361. [Abstract]

Mitochondrial function of Hep3B cells treated with OSW-1 (12.5, 25, 50 ng/mL).

OSW-1 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2025 May 22;30(1):361. [Abstract]

Intracellular ROS levels were measured using flow cytometry treated with OSW-1 (12.5, 25, 50 ng/mL).

OSW-1 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2025 May 22;30(1):361. [Abstract]

Western blotting of apoptosis-associated proteins following OSW-1 (12.5, 25, 50 ng/mL) treatment.

OSW-1 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2025 May 22;30(1):361. [Abstract]

mRNA expression of UCP2 was determined by reverse transcription-quantitative PCR treated with OSW-1 (12.5 ng/mL, 24, 48, 72 h).
bioRxiv

Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C. [Abstract]

2025 Feb 26:2024.06.08.598070. PMID: 38895395
bioRxiv

2024 Jan 16.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (114.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1454 mL

5.7272 mL

11.4544 mL

5 mM

0.2291 mL

1.1454 mL

2.2909 mL

10 mM

0.1145 mL

0.5727 mL

1.1454 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[2]

To observe the effect of OSW-1 on cell viability, the colon cancer cell lines LoVo and SW480 cells are seeded in 96-well plates at a concentration of 1×10⁵ cells/well. Following overnight incubation, the cells are treated with several concentrations of OSW-1 (11.25, 22.5, 45, 90, 180 ng/mL) and incubated at 37°C in 5% CO₂ for 24, 48, and 72 h. Cell viability analysis is determined using a Cell Counting Kit-8 Assay. Each assay is performed in quintuplicate and repeated three times^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Four-week-old male nude mice are used. Animals are acclimatized to the animal housing facility for a period of 7 days before the beginning of the experiments. LoVo human colon cancer cells (5x10⁶ cells in 100 μL) are injected subcutaneously into the right flank of 18 nude mice. When the tumor becomes palpable, the nude mice are randomized into two groups: i) intraperitoneal injection of PBS (500 μL) daily in 9 nude mice; and ii) intraperitoneal injection of OSW-1 (0.01 mg/kg diluted in PBS in 500 μL) daily in 9 nude mice. The body weights of the animals and tumor size are recorded every day, and the tumor volume is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Burgett AW, et al. Natural products reveal cancer cell dependence onoxysterol-binding proteins.Nat Chem Biol. 2011 Aug 7;7(9):639-47. [Content Brief]

[2]. Zhang Y, et al, Effective cytotoxic activity of OSW-1 on colon cancer by inducing apoptosis in vitro and in vivo.Oncol Rep. 2017 Jun;37(6):3509-3519. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1454 mL	5.7272 mL	11.4544 mL	28.6359 mL
	5 mM	0.2291 mL	1.1454 mL	2.2909 mL	5.7272 mL
	10 mM	0.1145 mL	0.5727 mL	1.1454 mL	2.8636 mL
	15 mM	0.0764 mL	0.3818 mL	0.7636 mL	1.9091 mL
	20 mM	0.0573 mL	0.2864 mL	0.5727 mL	1.4318 mL
	25 mM	0.0458 mL	0.2291 mL	0.4582 mL	1.1454 mL
	30 mM	0.0382 mL	0.1909 mL	0.3818 mL	0.9545 mL
	40 mM	0.0286 mL	0.1432 mL	0.2864 mL	0.7159 mL
	50 mM	0.0229 mL	0.1145 mL	0.2291 mL	0.5727 mL
	60 mM	0.0191 mL	0.0955 mL	0.1909 mL	0.4773 mL
	80 mM	0.0143 mL	0.0716 mL	0.1432 mL	0.3579 mL
	100 mM	0.0115 mL	0.0573 mL	0.1145 mL	0.2864 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

OSW-1

Publications Citing Use of MedChemExpress (MCE) OSW-1

Activité biologique

Chemical Information

Publications (5)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

OSW-1 Related Classifications

HY-101213 Related Classifications